GC
FLNA

Guggenheim Capital’s Filana Therapeutics FLNA Stock Holding History

Guggenheim Capital’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-29,808
Closed -$839K – 2026
2022
Q2 		$839K Sell
29,808
-1,064
-3% -$26.9K 0.01% 1308
2022
Q1 		$1.15M Sell
30,872
-3,974
-11% -$168K 0.01% 1294
2021
Q4 		$1.52M Buy
34,846
+9,149
+36% +$480K 0.01% 1187
2021
Q3 		$1.59M Buy
+25,697
New +$2.14M 0.01% 1167
2015
Q2 		– Sell
-2,299
Closed -$31K – 3087
2015
Q1 		$31K Buy
+2,299
New +$31K ﹤0.01% 2970

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Guggenheim Capital's FLNA Position: Q3 2022 in Review

Guggenheim Capital sold out of Filana Therapeutics (FLNA) in Q3 2022, closing a stake of 29,808 shares — an estimated $839K sold.

Guggenheim Capital first reported a position in FLNA in Q1 2015 and held it in 5 quarters. The position peaked at $1.59M in Q3 2021. 175 funds tracked by Wall St. Rank hold FLNA as of Q3 2022.

  • Guggenheim Capital reported no remaining Filana Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Guggenheim Capital sold 29,808 Filana Therapeutics shares in Q3 2022, an estimated $839K.
  • Guggenheim Capital first reported a position in Filana Therapeutics in Q1 2015 and held it in 5 quarters.
  • Guggenheim Capital's Filana Therapeutics position peaked at $1.59M in Q3 2021.
  • 175 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2022.

Based on Guggenheim Capital's 13F filing for Q3 2022, filed 14 Nov 2022.